According to Zhitong Finance App, Yaojie Ankang-B (02617.HK) announced that the application for marketing of tengotinib tablets has been accepted by the Drug Evaluation Center of the China National Drug Administration. It is intended to be used to treat adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received at least one systematic treatment and treatment with FGFR inhibitors in the past. Previously, tengotinib tablets were approved for inclusion in the list of priority review varieties and the list of breakthrough treatment varieties.

According to Zhitong Finance App, Yaojie Ankang-B (02617.HK) announced that the application for marketing of tengotinib tablets has been accepted by the Drug Evaluation Center of the China National Drug Administration. It is intended to be used to treat adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received at least one systematic treatment and treatment with FGFR inhibitors in the past. Previously, tengotinib tablets were approved for inclusion in the list of priority review varieties and the list of breakthrough treatment varieties.